Comparative efficacy and safety analysis of Lynparza and Fluzoparib

Olaparib (Olaparib) and Fluzoparib (Fluzoparib) are both polyADPribose polymerase inhibitors (PARPinhibitor), by blocking the DNA single-strand break repair mechanism, increasing the accumulation of DNA damage in cancer cells, thereby inducing cancer cell apoptosis. Both are used to treat tumors related to BRCA mutations, including ovarian cancer, breast cancer and some prostate cancer patients. Lynparib is the first PARP inhibitor to be widely approved globally and has mature clinical applications; fluzoparib is a new domestically developed PARP inhibitor with a similar structure to olaparib, but there are differences in drug metabolism, dosage forms and some clinical indications.

Comparison of indications and efficacy

Olaparib is mainly used for the maintenance treatment of BRCA mutated advanced ovarian cancer patients, including patients with platinum-sensitive relapse. In the pivotal Phase III clinical trialSOLO-1, olaparib significantly prolonged the median progression-free survival (PFS) in the treatment-naïve settingBRCAmutated advanced ovarian cancer, the medianPFS reached 56 months, compared with only 13.8 months in the control group. Fluzoparib showed efficacy in platinum-sensitive relapsed ovarian cancer in clinical trials, with a PFS of approximately 20–22 months, the overall response rate (ORR) can reach about 60%. Overall, olaparib is more effective in initial maintenance treatment, while fluzoparib shows better anti-tumor activity in relapsed or drug-resistant patient groups, especially in terms of domestic patient accessibility and long-term treatment options.

Safety and Tolerability Comparison

The adverse reactions of olaparib mainly include anemia, thrombocytopenia, nausea, vomiting, fatigue and loss of appetite. Some patients may develop interstitial lung disease or severe hematological toxicity. The common side effects of fluzoparib are similar to those of olaparib, but the overall tolerability is slightly better and the incidence of serious adverse events is lower. Clinical practice shows that fluzoparib has a large space for dose adjustment, and side effects can be controlled through intermittent administration or dose reduction while maintaining the anti-tumor effect. Both require regular monitoring of blood routine, liver and kidney function and hematological indicators during long-term maintenance treatment to ensure medication safety.

Clinical application and individualized selection

In clinical practice, the choice of olaparib or fluzoparib needs to be based on the patient's previous treatment history, tumorBRCA mutation status, drug resistance and economic factors. For patients with newly treated BRCA mutated advanced ovarian cancer, olaparib is the first-choice maintenance treatment drug with significant efficacy and sufficient data. For patients with recurrent or drug-resistant disease, fluzoparib can be an effective alternative, especially for patients with limited access to imported drugs or high financial pressure. Individualized treatment plans need to comprehensively consider efficacy, safety and patient compliance. Through regular follow-up and monitoring, the dosage and course of treatment should be optimized to maximize survival benefits and improve quality of life.

In general, olaparib and fluzoparib have similar anti-tumor mechanisms and are both PARP inhibitors, but there are differences in indications, persistence of efficacy and tolerability. Lynparib showed superior efficacy in treatment-naïve maintenance therapy, whereas fluzoparib had advantages in terms of relapse or domestic accessibility. Both require attention to hematological and gastrointestinal adverse reactions. Through individualized dose adjustment and regular monitoring, they can provide safe, effective and long-term sustainable treatment options for patients with BRCA mutation-related tumors.